{"title":"Progresses in treatment of elderly patients with acute myeloid leukemia","authors":"Di Wu","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.06.011","DOIUrl":null,"url":null,"abstract":"Elderly patients with acute myeloid leukemia (AML) are difficult to treat due to higher proportion of high risk factors and the efficacy of conventional chemotherapy remains unsatisfying. In recent years, researches concerning risk stratification of elderly patients with AML have prompted the individualization of therapeutic approaches. Besides, the advent of hypomethylating agents(HMA), novel targeted drugs, immunotherapy and the improvement of hematopoietic stem cell transplantation (HSCT) have shown promising prospects in elevating remission and survival rates while lowering treatment-related toxicities, thus providing new orientations of the diagnosis and treatment of this special population. This article reviews literatures of progress in the treatment of elderly patients with AML in aspects of stratified evaluation, chemotherapy, HMA, molecular targeted therapy, immunotherapy, cyclin kinase inhibitors, HSCT, and so on. \n \n \nKey words: \nLeukemia, myeloid, acute; Aged; Geriatric assessment; Demethylation; Molecular targeted therapy; Immunotherapy; Hematopoietic stem cell transplantation","PeriodicalId":13774,"journal":{"name":"国际输血及血液学杂志","volume":"42 1","pages":"524-529"},"PeriodicalIF":0.0000,"publicationDate":"2019-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际输血及血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.06.011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Elderly patients with acute myeloid leukemia (AML) are difficult to treat due to higher proportion of high risk factors and the efficacy of conventional chemotherapy remains unsatisfying. In recent years, researches concerning risk stratification of elderly patients with AML have prompted the individualization of therapeutic approaches. Besides, the advent of hypomethylating agents(HMA), novel targeted drugs, immunotherapy and the improvement of hematopoietic stem cell transplantation (HSCT) have shown promising prospects in elevating remission and survival rates while lowering treatment-related toxicities, thus providing new orientations of the diagnosis and treatment of this special population. This article reviews literatures of progress in the treatment of elderly patients with AML in aspects of stratified evaluation, chemotherapy, HMA, molecular targeted therapy, immunotherapy, cyclin kinase inhibitors, HSCT, and so on.
Key words:
Leukemia, myeloid, acute; Aged; Geriatric assessment; Demethylation; Molecular targeted therapy; Immunotherapy; Hematopoietic stem cell transplantation
期刊介绍：
The International Journal of Transfusion and Hematology was founded in September 1978. It is a comprehensive academic journal in the field of transfusion and hematology, supervised by the National Health Commission and co-sponsored by the Chinese Medical Association, West China Second Hospital of Sichuan University, and the Institute of Transfusion Medicine of the Chinese Academy of Medical Sciences. The journal is a comprehensive academic journal that combines the basic and clinical aspects of transfusion and hematology and is publicly distributed at home and abroad. The International Journal of Transfusion and Hematology mainly reports on the basic and clinical scientific research results and progress in the field of transfusion and hematology, new experiences, new methods, and new technologies in clinical diagnosis and treatment, introduces domestic and foreign research trends, conducts academic exchanges, and promotes the development of basic and clinical research in the field of transfusion and hematology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
